Saito, Kenichi
Eisai (United States)
3 papers on CoChatORCID 0000-0001-9271-2379
Most cited papers
- Verified
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
Kudo, M., Finn, R. S., Qin, S., Han, K.-H., Ikeda, K., Piscaglia, F., Baron, A., Park, J.-W., Han, G., Jassem, J., et al. (2018) · The Lancet
Hepatocellular Carcinoma Treatment and PrognosisColorectal Cancer Treatments and Studies
Cited by 5,497
- Verified
Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma
Finn, R. S., Ikeda, M., Zhu, A. X., Sung, M. W., Baron, A. D., Kudo, M., Okusaka, T., Kobayashi, M., Kumada, H., Kaneko, S., et al. (2020) · Journal of Clinical Oncology
Hepatocellular Carcinoma Treatment and PrognosisCancer Immunotherapy and Biomarkers
Cited by 1,167
- Verified
Effect of vitamin K2 on the recurrence of hepatocellular carcinoma
Yoshida, H., Shiratori, Y., Kudo, M., Shiina, S., Mizuta, T., Kojiro, M., Yamamoto, K., Koike, Y., Saito, K., Koyanagi, N., et al. (2011) · Hepatology
Vitamin K Research StudiesHepatocellular Carcinoma Treatment and Prognosis
Cited by 127
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free